- Plans to initiate trial in second half of 2018
- Edasalonexent significantly slowed progression in Ph II trial
- Edasalonexent is being developed as monotherapy or for use in... read more
On April 6, 2018, BioGaia became the majority shareholder in MetaboGen with a 62 percent stake. After certain milestones were achieved, BioGaia has extended its ownership to 92 percent of the... read more
SIGA Technologies,... read more
Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that, following receipt of regulatory approvals, it has completed the previously announced agreement to acquire a 40 percent minority... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,